MVP 1.27% 40.0¢ medical developments international limited

Must begetting close to some news on this....

  1. 4,010 Posts.
    lightbulb Created with Sketch. 1394
    Must begetting close to some news on this.

    https://www.ema.europa.eu/en/docume...n-agreed-paediatric-investigation-plan_en.pdf
    Page 7

    Study 1
    A randomised, double blind, multi-centre, placebo-controlled study to evaluate the safety and efficacy of methoxyflurane for the treatment of acute pain in children from 12 to less than 18 years of age (and in adults) presenting to an Emergency Department with minor trauma (MEOF-001).

    Study 2
    A randomised, double-blind, multi-centre, placebo controlled study to evaluate safety and efficacy of methoxyflurane for the treatment of acute pain in children and adolescents from 6 to less than 18 years of age presenting to an Emergency Department with minor trauma (MEOF-002).

    Date of completion of the paediatric investigation plan: By July 2021
 
watchlist Created with Sketch. Add MVP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.